Werewolf Therapeutics HOWL Stock
Werewolf Therapeutics Price Chart
Werewolf Therapeutics HOWL Financial and Trading Overview
| Werewolf Therapeutics stock price | 0.79 USD |
| Previous Close | 7.35 USD |
| Open | 7.5 USD |
| Bid | 7.11 USD x 1100 |
| Ask | 7.94 USD x 900 |
| Day's Range | 7.38 - 8.14 USD |
| 52 Week Range | 1.57 - 8.19 USD |
| Volume | 239.55K USD |
| Avg. Volume | 276.97K USD |
| Market Cap | 321.63M USD |
| Beta (5Y Monthly) | 0.487 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.63 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 12.8 USD |
HOWL Valuation Measures
| Enterprise Value | 188.14M USD |
| Trailing P/E | N/A |
| Forward P/E | -5.3809524 |
| PEG Ratio (5 yr expected) | -0.71 |
| Price/Sales (ttm) | 12.502474 |
| Price/Book (mrq) | 2.5087218 |
| Enterprise Value/Revenue | 7.314 |
| Enterprise Value/EBITDA | -4.824 |
Trading Information
Werewolf Therapeutics Stock Price History
| Beta (5Y Monthly) | 0.487 |
| 52-Week Change | N/A |
| S&P500 52-Week Change | N/A |
| 52 Week High | 8.19 USD |
| 52 Week Low | 1.57 USD |
| 50-Day Moving Average | 4.92 USD |
| 200-Day Moving Average | 3.25 USD |
HOWL Share Statistics
| Avg. Volume (3 month) | 276.97K USD |
| Avg. Daily Volume (10-Days) | 213.55K USD |
| Shares Outstanding | 40.66M |
| Float | 14.58M |
| Short Ratio | 0.62 |
| % Held by Insiders | 7.10% |
| % Held by Institutions | 77.66% |
| Shares Short | 219.18K |
| Short % of Float | 1.19% |
| Short % of Shares Outstanding | 0.61% |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | September 30, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -144.97% |
| Operating Margin (ttm) | -156.87% |
| Gross Margin | -86.53% |
| EBITDA Margin | -151.59% |
Management Effectiveness
| Return on Assets (ttm) | -14.59% |
| Return on Equity (ttm) | -30.64% |
Income Statement
| Revenue (ttm) | 25.73M USD |
| Revenue Per Share (ttm) | 0.75 USD |
| Quarterly Revenue Growth (yoy) | 18.69% |
| Gross Profit (ttm) | N/A |
| EBITDA | -38999000 USD |
| Net Income Avi to Common (ttm) | -37295000 USD |
| Diluted EPS (ttm) | -1.1 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 130.06M USD |
| Total Cash Per Share (mrq) | 3.59 USD |
| Total Debt (mrq) | 52.19M USD |
| Total Debt/Equity (mrq) | 46.41 USD |
| Current Ratio (mrq) | 9.645 |
| Book Value Per Share (mrq) | 3.153 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -39897000 USD |
| Levered Free Cash Flow (ttm) | -30341500 USD |
Profile of Werewolf Therapeutics
| Country | United States |
| State | MA |
| City | Watertown |
| Address | 200 Talcott Ave |
| ZIP | 02472 |
| Phone | 617 952 0555 |
| Website | https://werewolftx.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 46 |
Werewolf Therapeutics, Inc., a biopharmaceutical company, develops therapeutics engineered to stimulate the body's immune system for the treatment of cancer. The company, through its proprietary PREDATOR platform, designs conditionally activated molecules that stimulate adaptive and innate immunity for addressing the limitations of conventional proinflammatory immune therapies. Its lead product candidates are WTX-124, a conditionally activated Interleukin-2 INDUKINE molecule that is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors; and WTX-330, a conditionally activated Interleukin-12 INDUKINE molecule, which is in Phase I clinical trial for the treatment of advanced or metastatic solid tumors and lymphoma. The company is also developing JZP898, a conditionally activated interferon alpha INDUKINE molecule for the treatment of cancer; and WTX-712, an IL-21 INDUKINE molecule for the treatment of cancer. Werewolf Therapeutics, Inc. was incorporated in 2017 and is headquartered in Watertown, Massachusetts.
Q&A For Werewolf Therapeutics Stock
What is a current HOWL stock price?
Werewolf Therapeutics HOWL stock price today per share is 0.79 USD.
How to purchase Werewolf Therapeutics stock?
You can buy HOWL shares on the NasdaqGS exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Werewolf Therapeutics?
The stock symbol or ticker of Werewolf Therapeutics is HOWL.
Which industry does the Werewolf Therapeutics company belong to?
The Werewolf Therapeutics industry is Biotechnology.
How many shares does Werewolf Therapeutics have in circulation?
The max supply of Werewolf Therapeutics shares is 44.83M.
What is Werewolf Therapeutics Price to Earnings Ratio (PE Ratio)?
Werewolf Therapeutics PE Ratio is now.
What was Werewolf Therapeutics earnings per share over the trailing 12 months (TTM)?
Werewolf Therapeutics EPS is -1.63 USD over the trailing 12 months.
Which sector does the Werewolf Therapeutics company belong to?
The Werewolf Therapeutics sector is Healthcare.
Werewolf Therapeutics HOWL included in indexes
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume |
|---|
| Name Name | Price Price |
24h% 7d chart 24h% & 7d |
VOL Volume | 24h low | 24h high | Volume | |
|---|---|---|---|---|---|---|---|
| {{ item.name }} {{ item.symbol }} | {{ item.price }} {{ item.price_usd }} |
{{ item.change_pct }}
|
{{ item.volume }} {{ item.volume_usd }} | {{ item.low }} {{ item.low_usd }} | {{ item.high }} {{ item.high_usd }} | {{ item.components_count }} - | {{ item.volume }} {{ item.volume_usd }} |
| NASDAQ Composite IXIC | 16550.61 USD — |
-5.97
|
8.29B USD — | 16533.04 USD — | 16889.34 USD — | — - | 8.29B USD — |
| NASDAQ Global Select Market Com NQGS | 8098.63 USD — |
-5.98
|
— — | 8089.65 USD — | 8265.47 USD — | — - | — — |
| NASDAQ Biotechnology NBI | 4130.78 USD — |
-1.87
|
— — | 4123.5 USD — | 4185.42 USD — | — - | — — |
| NASDAQ HealthCare IXHC | 920.53 USD — |
-2.33
|
— — | 917.85 USD — | 930.28 USD — | — - | — — |
| Stlmt ID NASDAQ Biotechnology NBX | 4153.28 USD — |
+1.21
|
— — | 4281.91 USD — | 4648.11 USD — | — - | — — |
- {{ link.label }} {{link}}